{"organizations": [], "uuid": "6c0bce9b4e88d7ebf0b611b6d60ac6cacd435607", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/30/pr-newswire-nordic-nanovector-rainer-boehm-md-elected-to-board-of-directors.html", "country": "US", "domain_rank": 767, "title": "Nordic Nanovector: Rainer Boehm, MD Elected to Board of Directors", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.708, "site_type": "news", "published": "2018-05-30T16:07:00.000+03:00", "replies_count": 0, "uuid": "6c0bce9b4e88d7ebf0b611b6d60ac6cacd435607"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/30/pr-newswire-nordic-nanovector-rainer-boehm-md-elected-to-board-of-directors.html", "ord_in_thread": 0, "title": "Nordic Nanovector: Rainer Boehm, MD Elected to Board of Directors", "locations": [], "entities": {"persons": [{"name": "rainer boehm", "sentiment": "negative"}, {"name": "ra", "sentiment": "negative"}, {"name": "boehm", "sentiment": "none"}, {"name": "ludvik sa", "sentiment": "none"}], "locations": [{"name": "norway", "sentiment": "none"}, {"name": "france", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}, {"name": "us", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "board of directors oslo", "sentiment": "negative"}, {"name": "nano", "sentiment": "negative"}, {"name": "cellectis sa", "sentiment": "none"}, {"name": "novartis pharma", "sentiment": "none"}, {"name": "humanigen inc", "sentiment": "none"}, {"name": "university of ulm", "sentiment": "none"}, {"name": "schiller university", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}, {"name": "novartis oncology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OSLO, Norway, May 30, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company's Annual General Meeting on 30 May 2018.\nMr Boehm is an oncology expert with nearly 30 years' product development, commercial and corporate development experience working at Novartis, where since 2014 he has held the role of Chief Commercial & Medical Affairs Officer of Novartis Pharma (Switzerland). He has also held various other senior roles regionally and globally within the Oncology and Pharmaceutical divisions, including Executive Vice President, North America of Novartis Oncology in the US from 2005-2010.\nDuring his tenure at Novartis, Mr Boehm oversaw the commercial launches of various oncology brands in the US and globally including Femara®, Zometa®, Glivec®, among others.\nMr Boehm is a member of the Board of Directors at Cellectis SA and Humanigen Inc.\nHe has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.\nLudvik Sandnes, Chairman of Nordic Nanovector, comments: \"The Board is very pleased to welcome Rainer as a member. We are sure that his extensive experience in oncology and commercialisation will be invaluable with regards to the future development of the Company.\"\nRainer Boehm added: \"I am excited to join the Board and provide strategic input as the Company progresses its lead candidate through clinical development towards commercialisation. Betalutin® could provide an important treatment option for non-Hodgkin's lymphoma patients and I look forward to working with the Board and the management through this important stage of development for the Company.\"\nFor further information, please contact:\nMalene Brondberg,\nVP, Investor Relations and Corporate Communications\nTel/Cell: + 44-7561-431-762\nEmail: ir@nordicnanovector.com\nMedia enquiries:\nMark Swallow\nDavid Dible\nIsabelle Andrews (Citigate Dewe Rogerson)\nTel: +44-207-638-9571\nEmail: nordicnanovector@citigatedr.co.uk\nAbout Nordic Nanovector:\nNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com\nThis information was brought to you by Cision http://news.cision.com\nhttp://news.cision.com/nordic-nanovector/r/nordic-nanovector---rainer-boehm--md-elected-to-board-of-directors,c2535261\nView original content: http://www.prnewswire.com/news-releases/nordic-nanovector--rainer-boehm-md-elected-to-board-of-directors-300656378.html\nSOURCE Nordic Nanovector", "external_links": ["http://www.prnewswire.com/news-releases/nordic-nanovector--rainer-boehm-md-elected-to-board-of-directors-300656378.html", "http://news.cision.com/", "http://www.nordicnanovector.com/", "http://news.cision.com/nordic-nanovector/r/nordic-nanovector---rainer-boehm--md-elected-to-board-of-directors,c2535261"], "published": "2018-05-30T16:07:00.000+03:00", "crawled": "2018-05-30T17:21:21.008+03:00", "highlightTitle": ""}